Does Benadryl Contribute to Dementia?
Yes, diphenhydramine (Benadryl) and other anticholinergic medications are associated with increased risk of cognitive decline and dementia in older adults, and should be avoided in adults over 65.
Guideline-Based Recommendations
The 2019 American Geriatrics Society Beers Criteria, the gold standard for medication appropriateness in older adults, classifies first-generation antihistamines like diphenhydramine as potentially inappropriate medications (PIMs) for older adults 1. While the provided excerpt doesn't explicitly detail diphenhydramine, the guideline framework emphasizes avoiding medications with strong anticholinergic properties in this population due to risks of cognitive impairment and delirium.
Evidence for Dementia Risk
Longitudinal Studies Show Clear Association
The strongest evidence comes from a 4-year French population-based cohort study (n=6,912) demonstrating that continuous anticholinergic drug use increases dementia risk by 65% (HR 1.65; 95% CI 1.00-2.73) 2. Critically, this study found:
- Women using anticholinergics showed 41% greater decline in verbal fluency (OR 1.41; 95% CI 1.11-1.79)
- Men showed 63% increased decline in visual memory (OR 1.63; 95% CI 1.08-2.47)
- Discontinuing anticholinergic drugs eliminated the increased dementia risk (HR 1.28; 95% CI 0.59-2.76), suggesting the effect may be reversible if caught early
A German cohort study (AgeCoDe) corroborated these findings with a hazard ratio of 2.081 for dementia in chronic anticholinergic users 3.
Acute Cognitive Effects Are Well-Documented
Even short-term diphenhydramine use causes measurable cognitive impairment:
- In hospitalized older patients (n=426), diphenhydramine increased delirium risk 1.7-fold (RR 1.7; 95% CI 1.3-2.3), with specific increases in inattention (RR 3.0), disorganized speech (RR 5.5), and altered consciousness (RR 3.1) 4
- A dose-response relationship exists—higher doses cause worse outcomes
- Neurophysiologic studies show diphenhydramine reduces alertness-sensitive brain potentials (N160, P300) in elderly subjects, indicating direct neurocognitive impairment 5
Community-Based Data Shows Increasing Use
A 10-year rural cohort study found over-the-counter diphenhydramine use increased from 0.4% to 7.6% as the population aged, with use significantly associated with cognitive impairment even after excluding those with dementia 6.
Mechanism of Harm
The mechanism likely involves:
- Disruption of compensated cholinergic transmission in pre-dementia stages of Alzheimer's disease
- Acceleration of neuroinflammation by interfering with the anti-inflammatory effects of cholinergic innervation 3
- Direct anticholinergic blockade affecting memory consolidation and attention networks
Clinical Algorithm for Management
For Patients Currently Using Diphenhydramine:
- Immediate assessment: Identify why they're taking it (sleep, allergies, nausea)
- Discontinue if possible: The dementia risk appears reversible with discontinuation 2
- Substitute with safer alternatives:
- For sleep: Sleep hygiene, melatonin, or non-anticholinergic options
- For allergies: Second-generation antihistamines (cetirizine, loratadine) which don't cross blood-brain barrier
- For nausea: Ondansetron or other non-anticholinergic antiemetics
For Prevention:
- Avoid prescribing or recommending diphenhydramine in adults ≥65 years
- Screen medication lists for all anticholinergic medications, not just diphenhydramine
- Educate patients that "over-the-counter" does not mean "safe for seniors"
Critical Caveats
The FDA label for diphenhydramine does not mention dementia risk 7, highlighting a gap between regulatory warnings and clinical evidence. The label warns about drowsiness, confusion risk in elderly, and advises caution with glaucoma and urinary retention, but understates long-term cognitive risks.
One recent 2025 study on benzodiazepines (not diphenhydramine specifically) found that apparent dementia associations disappeared after controlling for confounding conditions like depression and anxiety 8. However, this applies to benzodiazepines, not anticholinergics like diphenhydramine, which have more robust evidence for direct cognitive harm.
Bottom Line
Diphenhydramine should be considered a modifiable risk factor for dementia in older adults. The evidence supports both acute cognitive impairment and long-term dementia risk with continuous use, with potential reversibility upon discontinuation. Given safer alternatives exist for virtually all indications, there is no justification for chronic diphenhydramine use in adults over 65.